Rabbit anti-thymocyte globulin + Cyclosporine + Levamisole

This is a combination drug regimen consisting of three distinct immunosuppressive agents: Rabbit anti-thymocyte globulin (rATG), Cyclosporine, and Levamisole. **Rabbit Anti-thymocyte Globulin (rATG):** Purified, pasteurized immunoglobulin G obtained by immunizing rabbits with human thymocytes. It contains cytotoxic antibodies directed against antigens expressed on human T-lymphocytes. It is primarily used to prevent and treat organ transplant rejection, particularly for kidney transplants, by depleting T-cells. It also has non-depleting immunomodulatory activities, including the induction of regulatory T cells and inhibition of T-cell chemotaxis. **Cyclosporine:** A well-known immunosuppressant commonly used in organ transplantation to prevent rejection, often in combination with other agents. It inhibits calcineurin, preventing T-cell activation. **Levamisole:** Originally an anthelmintic agent, it also exhibits immunomodulatory effects. It can enhance immune responses by affecting the activation and maturation of dendritic cells and T cells and has been shown to shift the immune balance toward Th1 responses by inducing IL-12 secretion. **The Combination:** This combination appears to be an immunomodulatory regimen potentially used in specific transplantation protocols or research settings. It would leverage rATG's T-cell depletion and immunomodulation, Cyclosporine's calcineurin inhibition and T-cell activation prevention, and Levamisole's immune response modulation. The provided search results do not explicitly describe this specific three-drug combination as a standard treatment protocol or provide information about its clinical trials or approval status, suggesting it may be an experimental or research-specific regimen.

Other names

Optimized Standard ProtocolrATG + CSA + LMS protocol